Nonapeptide-1
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Nonapeptide-1 (marketed as Melanostatine) is a pigment-pathway peptide alongside Decapeptide-12, targeting melanocyte signaling rather than the tyrosinase enzyme directly.
What does it do in my body?
Nonapeptide-1 antagonizes α-MSH at the MC1R receptor on melanocytes, reducing cAMP-mediated activation of tyrosinase and downstream melanin synthesis.
How can it help me?
- Where the science stands: Moderate — 4 studies, 1 RCT (tested as part of a proprietary combination product, not isolated)
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-effect data specific to Nonapeptide-1 in isolation was captured — the RCT tested the proprietary combination product, not the isolated peptide. Family-wide read: topical delivery carries a benign safety record.
Regulatory status: Cosmetic-grade OTC topical ingredient — not an FDA-reviewed drug.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Topical-only cosmetic ingredient, tested in the referenced RCT as part of a proprietary combination product used for melasma maintenance vs. sunscreen. No standalone concentration figure was captured in the source profile.
What should I avoid combining — and what's synergistic?
Nonapeptide-1 doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
Real RCT signal for melasma maintenance — with the usual cosmetic-trial caveat that it was tested inside a combination product, not in isolation.
| Class | Pigment / brightening peptide — topical cosmetic peptide |
| Mechanism (one line) | Antagonizes α-MSH at the MC1R receptor on melanocytes → reduces cAMP-mediated tyrosinase activation and downstream melanin synthesis |
| Evidence base | Moderate — 4 studies, 1 RCT (tested as part of a proprietary combination product, not isolated) |
| Safety record | Topical-only; benign safety record (Safety: green) |
| Regulatory status | Cosmetic-grade OTC skincare ingredient, not an FDA-reviewed drug |
What it is
Nonapeptide-1 (marketed as Melanostatine) is a pigment-pathway peptide alongside Decapeptide-12, targeting melanocyte signaling rather than the tyrosinase enzyme directly.
How it works
Nonapeptide-1 antagonizes α-MSH at the MC1R receptor on melanocytes, reducing cAMP-mediated activation of tyrosinase and downstream melanin synthesis.
What the research shows
Public profile grade: Moderate — 4 studies, 1 RCT. The RCT (Chatterjee et al., 2021, Indian J Dermatol Venereol Leprol, PMID 34379946) tested a proprietary combination containing Nonapeptide-1 vs. sunscreen for melasma maintenance and found it efficacious — so the peptide is one component of the tested formula, not isolated. Supporting in-vitro work covers the α-MSH/MC1R melanogenesis pathway (e.g. PMID 35645678, PMID 39260749, both).
OHM’s internal 0035 categorization pass grades Nonapeptide-1 Tier C / green / recommend-eligible (Mela-X / Lipotec).
Status: real RCT signal for melasma maintenance, with the usual cosmetic-trial caveat that it was tested in a combination product.
Real-world protocol
Topical-only cosmetic ingredient, tested in the referenced RCT as part of a proprietary combination product used for melasma maintenance vs. sunscreen. No standalone concentration figure was captured in the source profile.
Side effects & management
No adverse-effect data specific to Nonapeptide-1 in isolation was captured — the RCT tested the proprietary combination product, not the isolated peptide. Family-wide read: topical delivery carries a benign safety record.
Regulatory status
Cosmetic-grade OTC topical ingredient — not an FDA-reviewed drug.
Sources
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Moderate, 4 studies, 1 RCT. Studies cited: Chatterjee et al., 2021, Indian J Dermatol Venereol Leprol, PMID 34379946; PMID 35645678; PMID 39260749.
- OHM tier/safety grading: Tier C / green / recommend-eligible, Mela-X / Lipotec.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Decapeptide-12
Sources & references
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Moderate, 4 studies, 1 RCT. Studies cited: Chatterjee et al., 2021, Indian J Dermatol Venereol Leprol, PMID 34379946; PMID 35645678; PMID 39260749.
- OHM tier/safety grading: Tier C / green / recommend-eligible, Mela-X / Lipotec.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Decapeptide-12